JEMPERLI
PeakBLAINJECTIONINJECTABLEPriority Review
Approved
Aug 2021
Lifecycle
Peak
Competitive Pressure
30/100
Intelligence
5/8 — Good Coverage
Priority Review
JEMPERLI by GSK is pd-1 ligands, pd-l1 and pd-l2, to the pd-1 receptor found on t cells inhibits t-cell proliferation and cytokine production. Approved for recurrent endometrial cancer (ec), advanced ec, determined by an fda-approved test and 5 more indications. First approved in 2021.
Mechanism of Action
PD-1 ligands, PD-L1 and PD-L2, to the PD-1 receptor found on T cells inhibits T-cell proliferation and cytokine production. Upregulation of PD-1 ligands occurs in some tumors, and signaling through this pathway can contribute to inhibition of active T-cell immune surveillance of tumors.…
Indications (7)
Worked on JEMPERLI at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.